These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 33197078)

  • 1. Safety, pharmacokinetics and pharmacodynamics of SBT-020 in patients with early stage Huntington's disease, a 2-part study.
    van Diemen MPJ; Hart EP; Abbruscato A; Mead L; van Beelen I; Bergheanu SC; Hameeteman PW; Coppen E; Winder JY; Moerland M; Kan H; van der Grond J; Webb A; Roos RAC; Groeneveld GJ
    Br J Clin Pharmacol; 2021 May; 87(5):2290-2302. PubMed ID: 33197078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain Bio-Energetic State Does Not Correlate to Muscle Mitochondrial Function in Huntington's Disease.
    van Diemen MPJ; Hart EP; Hameeteman PW; Coppen EM; Winder JY; den Heijer J; Moerland M; Kan H; van der Grond J; Webb A; Roos RAC; Groeneveld GJ
    J Huntingtons Dis; 2020; 9(4):335-344. PubMed ID: 33325391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial.
    Huntington Study Group Reach2HD Investigators
    Lancet Neurol; 2015 Jan; 14(1):39-47. PubMed ID: 25467848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Huntingtin Expression in Patients with Huntington's Disease.
    Tabrizi SJ; Leavitt BR; Landwehrmeyer GB; Wild EJ; Saft C; Barker RA; Blair NF; Craufurd D; Priller J; Rickards H; Rosser A; Kordasiewicz HB; Czech C; Swayze EE; Norris DA; Baumann T; Gerlach I; Schobel SA; Paz E; Smith AV; Bennett CF; Lane RM;
    N Engl J Med; 2019 Jun; 380(24):2307-2316. PubMed ID: 31059641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat.
    Clemens LE; Weber JJ; Wlodkowski TT; Yu-Taeger L; Michaud M; Calaminus C; Eckert SH; Gaca J; Weiss A; Magg JC; Jansson EK; Eckert GP; Pichler BJ; Bordet T; Pruss RM; Riess O; Nguyen HP
    Brain; 2015 Dec; 138(Pt 12):3632-53. PubMed ID: 26490331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Vivo Multidimensional Brain Imaging in Huntington's Disease Animal Models.
    Flament J; Hantraye P; Valette J
    Methods Mol Biol; 2018; 1780():285-301. PubMed ID: 29856025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study.
    Reilmann R; McGarry A; Grachev ID; Savola JM; Borowsky B; Eyal E; Gross N; Langbehn D; Schubert R; Wickenberg AT; Papapetropoulos S; Hayden M; Squitieri F; Kieburtz K; Landwehrmeyer GB; ;
    Lancet Neurol; 2019 Feb; 18(2):165-176. PubMed ID: 30563778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's disease.
    Süssmuth SD; Haider S; Landwehrmeyer GB; Farmer R; Frost C; Tripepi G; Andersen CA; Di Bacco M; Lamanna C; Diodato E; Massai L; Diamanti D; Mori E; Magnoni L; Dreyhaupt J; Schiefele K; Craufurd D; Saft C; Rudzinska M; Ryglewicz D; Orth M; Brzozy S; Baran A; Pollio G; Andre R; Tabrizi SJ; Darpo B; Westerberg G;
    Br J Clin Pharmacol; 2015 Mar; 79(3):465-76. PubMed ID: 25223731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial.
    de Yebenes JG; Landwehrmeyer B; Squitieri F; Reilmann R; Rosser A; Barker RA; Saft C; Magnet MK; Sword A; Rembratt A; Tedroff J;
    Lancet Neurol; 2011 Dec; 10(12):1049-57. PubMed ID: 22071279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Huntington's Disease and Mitochondria.
    Jodeiri Farshbaf M; Ghaedi K
    Neurotox Res; 2017 Oct; 32(3):518-529. PubMed ID: 28639241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitochondrial Dysfunction in Huntington's Disease: Pathogenesis and Therapeutic Opportunities.
    Sharma A; Behl T; Sharma L; Aelya L; Bungau S
    Curr Drug Targets; 2021; 22(14):1637-1667. PubMed ID: 33655829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural and functional changes of the visual cortex in early Huntington's disease.
    Coppen EM; Grond JV; Hafkemeijer A; Barkey Wolf JJH; Roos RAC
    Hum Brain Mapp; 2018 Dec; 39(12):4776-4786. PubMed ID: 30144208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased nuclear DNA damage precedes mitochondrial dysfunction in peripheral blood mononuclear cells from Huntington's disease patients.
    Askeland G; Dosoudilova Z; Rodinova M; Klempir J; Liskova I; Kuśnierczyk A; Bjørås M; Nesse G; Klungland A; Hansikova H; Eide L
    Sci Rep; 2018 Jun; 8(1):9817. PubMed ID: 29959348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prefrontal executive function associated coupling relates to Huntington's disease stage.
    Unschuld PG; Liu X; Shanahan M; Margolis RL; Bassett SS; Brandt J; Schretlen DJ; Redgrave GW; Hua J; Hock C; Reading SA; van Zijl PC; Pekar JJ; Ross CA
    Cortex; 2013; 49(10):2661-73. PubMed ID: 23906595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of glial genes involved in synaptic function mitigates Huntington's disease pathogenesis.
    Onur TS; Laitman A; Zhao H; Keyho R; Kim H; Wang J; Mair M; Wang H; Li L; Perez A; de Haro M; Wan YW; Allen G; Lu B; Al-Ramahi I; Liu Z; Botas J
    Elife; 2021 Apr; 10():. PubMed ID: 33871358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction in mitochondrial DNA copy number in peripheral leukocytes after onset of Huntington's disease.
    Petersen MH; Budtz-Jørgensen E; Sørensen SA; Nielsen JE; Hjermind LE; Vinther-Jensen T; Nielsen SM; Nørremølle A
    Mitochondrion; 2014 Jul; 17():14-21. PubMed ID: 24836434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitochondrial and Redox-Based Therapeutic Strategies in Huntington's Disease.
    Fão L; Rego AC
    Antioxid Redox Signal; 2021 Mar; 34(8):650-673. PubMed ID: 32498555
    [No Abstract]   [Full Text] [Related]  

  • 18. Mitochondrial SIRT3 confers neuroprotection in Huntington's disease by regulation of oxidative challenges and mitochondrial dynamics.
    Naia L; Carmo C; Campesan S; Fão L; Cotton VE; Valero J; Lopes C; Rosenstock TR; Giorgini F; Rego AC
    Free Radic Biol Med; 2021 Feb; 163():163-179. PubMed ID: 33285261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone Deacetylase Inhibitors Protect Against Pyruvate Dehydrogenase Dysfunction in Huntington's Disease.
    Naia L; Cunha-Oliveira T; Rodrigues J; Rosenstock TR; Oliveira A; Ribeiro M; Carmo C; Oliveira-Sousa SI; Duarte AI; Hayden MR; Rego AC
    J Neurosci; 2017 Mar; 37(10):2776-2794. PubMed ID: 28123081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brain metabolite alterations and cognitive dysfunction in early Huntington's disease.
    Unschuld PG; Edden RA; Carass A; Liu X; Shanahan M; Wang X; Oishi K; Brandt J; Bassett SS; Redgrave GW; Margolis RL; van Zijl PC; Barker PB; Ross CA
    Mov Disord; 2012 Jun; 27(7):895-902. PubMed ID: 22649062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.